Last reviewed · How we verify

DA-EPOCH-R followed by Nivolumab

Stichting Hemato-Oncologie voor Volwassenen Nederland · Phase 2 active Small molecule

DA-EPOCH-R followed by Nivolumab is a PD-1 inhibitor Small molecule drug developed by Stichting Hemato-Oncologie voor Volwassenen Nederland. It is currently in Phase 2 development for Relapsed or refractory diffuse large B-cell lymphoma, Classical Hodgkin lymphoma. Also known as: Opdivo.

DA-EPOCH-R is a chemotherapy regimen that combines etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide, followed by Nivolumab, a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.

DA-EPOCH-R is a chemotherapy regimen that combines etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide, followed by Nivolumab, a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction. Used for Relapsed or refractory diffuse large B-cell lymphoma, Classical Hodgkin lymphoma.

At a glance

Generic nameDA-EPOCH-R followed by Nivolumab
Also known asOpdivo
SponsorStichting Hemato-Oncologie voor Volwassenen Nederland
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

DA-EPOCH-R is a chemotherapy regimen that combines etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide. Nivolumab is a monoclonal antibody that targets the PD-1 receptor, preventing the PD-1/PD-L1 interaction and thereby enhancing the immune response against cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DA-EPOCH-R followed by Nivolumab

What is DA-EPOCH-R followed by Nivolumab?

DA-EPOCH-R followed by Nivolumab is a PD-1 inhibitor drug developed by Stichting Hemato-Oncologie voor Volwassenen Nederland, indicated for Relapsed or refractory diffuse large B-cell lymphoma, Classical Hodgkin lymphoma.

How does DA-EPOCH-R followed by Nivolumab work?

DA-EPOCH-R is a chemotherapy regimen that combines etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide, followed by Nivolumab, a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.

What is DA-EPOCH-R followed by Nivolumab used for?

DA-EPOCH-R followed by Nivolumab is indicated for Relapsed or refractory diffuse large B-cell lymphoma, Classical Hodgkin lymphoma.

Who makes DA-EPOCH-R followed by Nivolumab?

DA-EPOCH-R followed by Nivolumab is developed by Stichting Hemato-Oncologie voor Volwassenen Nederland (see full Stichting Hemato-Oncologie voor Volwassenen Nederland pipeline at /company/stichting-hemato-oncologie-voor-volwassenen-nederland).

Is DA-EPOCH-R followed by Nivolumab also known as anything else?

DA-EPOCH-R followed by Nivolumab is also known as Opdivo.

What drug class is DA-EPOCH-R followed by Nivolumab in?

DA-EPOCH-R followed by Nivolumab belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is DA-EPOCH-R followed by Nivolumab in?

DA-EPOCH-R followed by Nivolumab is in Phase 2.

What are the side effects of DA-EPOCH-R followed by Nivolumab?

Common side effects of DA-EPOCH-R followed by Nivolumab include Fatigue, Nausea, Diarrhea, Rash, Pyrexia.

What does DA-EPOCH-R followed by Nivolumab target?

DA-EPOCH-R followed by Nivolumab targets PD-1 and is a PD-1 inhibitor.

Related